The strong revenue beat and guidance raise support the bull case for XDEMVY's commercial trajectory, but the massive EPS miss and $125M dilutive PIPE create near-term overhang. Watch for details on the Alkeus acquisition terms and integration costs, and monitor Q3 prescription trends to confirm demand momentum.
Price Chart
Executive Summary
Tarsus reported Q2 2026 product sales of $173.9M (+69% YoY) and raised full-year XDEMVY guidance to $685-705M, but EPS of -$0.43 missed consensus of -$0.20 by 119%. The company also announced a pending acquisition of Alkeus Pharmaceuticals and a $125M private placement, expanding into retina with a Phase 3 Stargardt disease program. The strong revenue beat and guidance raise are offset by the massive EPS miss and dilution from the financing, creating a mixed picture for traders.
Key Financial Metrics
Key Facts
- Q2 2026 XDEMVY net product sales of $173.9M, up >69% YoY from $102.7M
- Full-year 2026 XDEMVY guidance raised to $685-705M from prior $670-700M
- GAAP EPS of -$0.43 missed consensus of -$0.20 (-119.4% surprise)
- Net loss of $18.6M vs $20.3M in prior year; operating loss widened to $19.9M
- Cash, equivalents and marketable securities at $449.7M as of June 30, 2026
- Announced pending acquisition of Alkeus Pharmaceuticals (ALK-001 for Stargardt disease)
- Priced $125M private placement financing with top-tier funds
- Completed acquisition of iRenix Medical (IRX-101 ocular antiseptic)
- SG&A expenses surged to $150.7M (+46% YoY) on DTC and commercial expansion
- R&D expenses nearly doubled to $31.0M (+99% YoY) driven by TP-05 Calliope trial
Financial Impact
Q2 product sales $173.9M (+69% YoY); EPS -$0.43 vs consensus -$0.20; guidance raised to $685-705M; $125M PIPE financing
Risk Factors
- Massive EPS miss (-119%) signals operating leverage is deteriorating faster than expected
- $125M PIPE financing dilutes existing shareholders and adds execution risk for the Alkeus acquisition
- SG&A spending growth (+46% YoY) may not sustain if revenue growth decelerates
- Pipeline catalysts (TP-04, TP-05, IRX-101) are years away from commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001819790-26-000063 |
| Document: tars-20260806.htm | 0001819790-26-000063 |
| Document: 0001819790-26-000063-index-headers.html | 0001819790-26-000063 |
| Document: 0001819790-26-000063-index.html | 0001819790-26-000063 |
| Document: 0001819790-26-000063.txt | 0001819790-26-000063 |
| 8-K Data (Synthetic) | 0001819790-26-000063 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $82.77 $77.64 | ▼ −6.20% | ▼ −5.54% | $73.61 (−11.06%) |
Sep 3, 2026 29d ago | Insider Cluster | $83.21 $79.31 | ▼ −4.68% | ▼ −3.53% | $73.61 (−11.53%) |
Sep 2, 2026 29d ago | 144 | $82.76 $81.12 | ▲ +1.98% | ▲ +1.02% | $73.61 (+11.05%) |
Sep 1, 2026 4w ago | 144 | $82.76 $81.12 | ▲ +1.98% | ▲ +1.02% | $73.61 (+11.05%) |
Aug 19, 2026 6w ago | 144 | $73.44 $70.65 | ▼ −3.80% | ▼ −3.41% | $73.61 (+0.24%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | 8-K | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | Press Release | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
Aug 6, 2026 8w ago | Press Release | $65.33 $68.88 | ▲ +5.43% | ▲ +4.22% | $73.61 (+12.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access